Neervannan Seshadri sold $388K of TARS

Neervannan Seshadri (Chief Operating Officer) sold 4,564 shares of Tarsus Pharmaceuticals, Inc. (TARS) at $85.00 ($0.39M total) on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Neervannan Seshadri
Published Sep 9, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
high confidence
Mentioned
$TARS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

Provides transparency on insider holdings; minimal price effect.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing that prompted the sale.

Relevance 3/10Novelty 5/10Timing: post‑market Sep 4 transaction, filed Sep 9

Background

Form 4 filing reveals insider transaction details for Tarsus Pharmaceuticals.

Company-level read

Ticker impact

$TARSNeutralHigh confidence
Context

COO Neervannan Seshadri sold 4,564 shares for $387,940 via a 10b5-1 plan.

Expected impact

No significant impact; price may remain flat.

Evidence & confidence

Sale size is small relative to float and disclosed via pre-arranged plan.

Market effects

No immediate sector impact; insider sale is routine for pharma.

Limited to US market where TARS trades.

Low; isolated to the company.

Counterpoint

Even small insider sales can signal confidence issues; watch for further disposals.

Key entities

  • Neervannan Seshadri

    Chief Operating Officer of Tarsus Pharmaceuticals

  • Tarsus Pharmaceuticals, Inc.

    Biopharma company listed on NASDAQ under ticker TARS

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.